Loading institutional data...
Loading institutional data...
Held by 532 of 5,944 reporting institutions (97th percentile) — extremely crowded.
Data as of Q1 2026
Loading snapshot...
Loading financials...
Loading valuation...
Loading quality & risk...
Loading dividends & returns...
Loading capital allocation...
Loading debt & leverage...
Loading performance...
Loading peer comparison...
Loading ownership map...
Loading crowding analysis...
Loading conviction analysis...
Loading buy/sell flow...
Loading ownership trends...
Loading top holders...
Loading top holders...
Total shares institutions bought (green) vs sold (red) each quarter across all holders.
Inferred from quarter-over-quarter change in each fund's 13F position (new stakes count as buys, exits as sells). Not tick-level trades.
Solve the discounted cash flow backwards, then stress-test the assumptions.
To be worth $281.67 today, the market must believe free cash flow compounds 13.0%/yr for a decade (off $462M normalized FCF).
The market's 13.0% is more optimistic than its 9-yr track record.
2-stage DCF · 0.05B shares · net debt -$214M
mean 11.4% · volatility σ 26% · implied rate exceeded in 5/9 yrs
Central path = implied 13.0%/yr growth; shaded band = ±1σ (26%) of this company's historical FCF volatility, widening with time. The wider the band, the less certain the growth.
Reverse DCF: rather than guessing a fair value, we solve for the growth the current price implies, then you stress-test the assumptions. Enterprise value of the FCF stream, less net debt, ÷ shares. Educational — not a recommendation.
Is the value real, and is the business safe? Academic scores + earnings quality + solvency, from SEC filings.
4/8 of the 9 checks — 1 couldn't be scored (see above), so the score is out of the 8 with data.
Safe > 2.99 · grey 1.81–2.99 · distress < 1.81
Needs granular two-year detail (receivables, PP&E, D&A, SG&A) — not fully reported.
Cash-conversion data unavailable. Lower/negative accruals = higher quality (Sloan).
Interest coverage is thin — monitor; leverage rising year-over-year.
F-Score (0–9 fundamental momentum), Altman Z (distress risk), and Beneish M (earnings-manipulation screen) are academic models computed from the SEC filings. Screens and context — educational, not recommendations.
What the company returns to shareholders — and whether it's covered by cash.
No dividend to cover. Last year: $0 dividends + $361M buybacks = $361M returned on $518M FCF.
Yields use the latest fiscal-year dividends/buybacks over current market cap. Dividends and buybacks from the SEC cash-flow statement; payout coverage vs net income and free cash flow. Educational — not a recommendation.
How management deployed cash over 10 years — and what it earned on reinvestment.
A reinvestment story — most cash went back into growth rather than to shareholders.
Operating income fell despite reinvestment — a warning on capital productivity. Current ROIC on all capital: -5%. Rough measure (includes maintenance capex).
Cash uses aggregated from the SEC cash-flow statement over 10 fiscal years. "Return on reinvestment" is a rough proxy — operating-income change ÷ cumulative CapEx + M&A — and includes maintenance capex. Educational — not a recommendation.
How much the company owes, how it's trended, and how comfortably it's serviced.
Cash of $214M covers the $1M due within a year 160.2× over. Scheduled principal only (excludes interest & revolver draws). As of 2025-12-27 (10-K).
Green ≤ 1.5× · amber ≤ 3× · red > 3× (leverage relative to cash earnings).
Thin coverage — earnings barely cover interest. Effective rate ~64475.3% on $166000 of debt.
Cash of $214M fully covers short-term debt of $166000.
Mostly short-term debt (balance-sheet current vs non-current split). See the maturity ladder above for the year-by-year repayment schedule.
Debt, cash, interest and equity from the SEC balance sheet & income statement. Effective rate = interest ÷ average debt. Maturity ladder from the SEC long-term-debt repayment schedule. Educational — not a recommendation.
EOD close · as of 2026-09-17
How a revenue dollar becomes profit — FY2025
Each value shows its share of revenue below it (common-size).
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $4.02B 100.0% | $4.05B 100.0% | $4.13B 100.0% | $3.98B 100.0% | $3.54B 100.0% | $2.92B 100.0% | $2.62B 100.0% | $2.27B 100.0% | $1.86B 100.0% | $1.68B 100.0% |
| Cost of Revenue | — | — | — | — | — | — | — | — | $289.7M 15.6% | $277.0M 16.5% |
| Cost of Products | — | — | — | — | — | — | — | — | $289.7M 15.6% | $277.0M 16.5% |
| Cost of Services | — | — | — | — | — | — | — | — | $865.6M 46.6% | $757.7M 45.1% |
| Selling, General & Admin | $743.1M 18.5% | $751.0M 18.5% | $747.9M 18.1% | $665.1M 16.7% | $619.9M 17.5% | $528.9M 18.1% | $517.6M 19.7% | $443.9M 19.6% | $371.3M 20.0% | $364.7M 21.7% |
| Operating Income | $25.2M 0.6% | $227.3M 5.6% | $617.3M 14.9% | $651.0M 16.4% | $589.9M 16.7% | $432.7M 14.8% | $351.2M 13.4% | $331.4M 14.6% | $288.3M 15.5% | $237.6M 14.1% |
| Interest Expense | $107.0M 2.7% | $126.3M 3.1% | $136.7M 3.3% | $59.3M 1.5% | $73.9M 2.1% | $86.4M 3.0% | $60.9M 2.3% | $63.8M 2.8% | $29.8M 1.6% | $27.7M 1.6% |
| Interest & Investment Income | $4.9M 0.1% | $8.6M 0.2% | $5.2M 0.1% | $780K 0.0% | $652K 0.0% | $834K 0.0% | $1.5M 0.1% | $812K 0.0% | $690K 0.0% | $1.3M 0.1% |
| Other Income (Expense), net | -$22.6M -0.6% | -$16.5M -0.4% | $95.5M 2.3% | $30.5M 0.8% | -$35.9M -1.0% | $100.0M 3.4% | $12.3M 0.5% | $13.3M 0.6% | $37.8M 2.0% | $11.8M 0.7% |
| Pretax Income | -$99.5M -2.5% | $93.1M 2.3% | $581.3M 14.1% | $623.0M 15.7% | $480.7M 13.6% | $447.1M 15.3% | $304.1M 11.6% | $281.7M 12.4% | $297.0M 16.0% | $222.9M 13.3% |
| Income Tax Expense | $42.7M 1.1% | $67.8M 1.7% | $100.9M 2.4% | $130.4M 3.3% | $81.9M 2.3% | $81.8M 2.8% | $50.0M 1.9% | $54.5M 2.4% | $171.4M 9.2% | $66.8M 4.0% |
| Net Income | -$144.3M -3.6% | $22.2M 0.5% | $474.6M 11.5% | $486.2M 12.2% | $391.0M 11.0% | $364.3M 12.5% | $252.0M 9.6% | $226.4M 10.0% | $123.4M 6.6% | $154.8M 9.2% |
| Per Share | ||||||||||
| EPS (Basic) | $-2.91 | $0.20 | $9.27 | $9.57 | $7.77 | $7.35 | $5.17 | $4.72 | $2.60 | $3.29 |
| EPS (Diluted) | $-2.91 | $0.20 | $9.22 | $9.48 | $7.60 | $7.20 | $5.07 | $4.62 | $2.54 | $3.23 |
| Weighted Avg Shares (Basic) | 49.6M | 51.4M | 51.2M | 50.8M | 50.3M | 49.5M | 48.7M | 47.9M | 47.5M | 47.0M |
| Weighted Avg Shares (Diluted) | 49.6M | 51.6M | 51.5M | 51.3M | 51.4M | 50.6M | 49.7M | 49.0M | 48.6M | 48.0M |
Source: SEC EDGAR XBRL filings (annual, fiscal year). Quarterly flow items are derived from cumulative filings; balance-sheet figures are as-of each period end. Ratios and margins are computed, not reported.
Top 40 institutional holders — bubble size is position value, color is the move since last quarter. Hover any holder for detail.
Drag any bubble to rearrange · size = dollar value of the position
EOD close · as of 2026-09-17
Is the profit real, and how strong is the balance sheet?
FY2025 · every deduction from revenue to net income
DuPont — the three levers
Watch the leverage lever — a chunk of ROE comes from the balance sheet.
What the company owes vs. what it holds
Year-by-year maturities aren't in SEC companyfacts (footnote-only), so this shows the debt/cash structure and net leverage instead.
Latest year: profit growth vs revenue growth
High operating leverage: profit moved 104.1× as fast as sales — great in an upturn, painful in a downturn.
Each line as % of revenue — the trend in color
| % of revenue | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| SG&A | 19.6 | 19.7 | 18.1 | 17.5 | 16.7 | 18.1 | 18.5 | 18.5 |
| Operating Income | 14.6 | 13.4 | 14.8 | 16.7 | 16.4 | 14.9 | 5.6 | 0.6 |
| Income Tax | 2.4 | 1.9 | 2.8 | 2.3 | 3.3 | 2.4 | 1.7 | 1.1 |
| Net Income | 10.0 | 9.6 | 12.5 | 11.0 | 12.2 | 11.5 | 0.5 | -3.6 |
Green = margin-favorable vs the row's own range · red = unfavorable.
The metrics that matter, over time
A 30-second read on CRL: price, valuation, headline fundamentals, and an auto-generated scorecard from SEC filings. Flags are rule-based signals, not recommendations.
Total return (dividends reinvested) vs the market, from quarter-end prices.
Above 0 = ahead of the S&P 500 since the window start; below 0 = behind. Rising means it's pulling ahead.
How far the stock fell below its prior peak. Deeper, longer drawdowns = a rougher ride to the same return.
Quarter-end, dividend-adjusted (total return). Beta & volatility from quarterly returns (annualized). Benchmark is the S&P 500 (SPY total return). Annual returns compound the quarters ending in each calendar year; the first and last years in a window may be partial. Past performance doesn't predict future results.
Ranked against 1085 sector peers with collected financials. Valuation from latest close × latest fiscal-year fundamentals; 13F conviction as of 2026-03-31.
Percentile is “goodness” within the peer set (100 = best). For valuation and leverage that means cheaper / less-levered ranks higher.
| Company | Mkt cap ▼ | P/E | EV/EBITDA | P/S | Rev gr | Gross | Net | ROE | ROIC | Net D/EBITDA | 13F |
|---|---|---|---|---|---|---|---|---|---|---|---|
| BCAX | $1.20T | — | — | — | — | — | — | -34.4% | -34.4% | — | 143 |
| LLY | $1.02T | 49.6× | — | 15.7× | 44.7% | 83.0% | 31.7% | 77.8% | 29.9% | — | 4,193 |
| AKTX | $916.2B | — | — | — | — | — | — | -61.1% | -61.1% | — | 1 |
| JNJ | $643.4B | 24.2× | — | 6.8× | 6.0% | 67.9% | 28.5% | 32.9% | 20.7% | — | 4,451 |
| ABBV | $464.4B | 111.2× | 33.2× | 7.6× | 8.6% | 70.2% | 6.9% | -129% | 6.6% | 4.2× | 3,895 |
| MRK | $362.6B | 19.9× | — | 5.6× | 1.3% | 74.8% | 28.1% | 34.7% | 17.9% | — | 3,594 |
| UNH | $340.0B | 28.4× | 19.7× | 0.8× | 11.8% | 88.7% | 2.7% | 12.0% | 6.8% | 3.9× | 2,891 |
| AZN | $252.6B | — | — | — | — | — | — | — | — | — | 1,248 |
| TMO | $244.5B | 36.5× | 31.5× | 5.5× | 3.9% | — | 15.0% | 12.6% | 7.0% | 4.9× | 2,481 |
| AMGN | $202.8B | 26.4× | 17.4× | 5.5× | 10.0% | 67.2% | 21.0% | 89.1% | 12.2% | 3.8× | 3,014 |
| GILD | $183.3B | 21.8× | 20.0× | 6.2× | 2.4% | 78.8% | 28.9% | 37.5% | 17.9% | 2.4× | 2,218 |
| ABT | $178.2B | 27.5× | 19.3× | 4.0× | 5.7% | 56.4% | 14.7% | 12.5% | 10.0% | 1.4× | 2,964 |
| PFE | $156.1B | 20.2× | — | 2.5× | -1.6% | 74.3% | 12.4% | 9.0% | 5.1% | — | 2,838 |
| DHR | $147.3B | 41.3× | 30.5× | 6.0× | 2.9% | 59.1% | 14.7% | 6.9% | 5.1% | 3.4× | 2,083 |
| ISRG | $135.8B | 48.6× | 37.3× | 13.5× | 20.5% | 66.0% | 28.4% | 16.0% | 16.0% | — | 2,190 |
| VRTX | $130.4B | 33.5× | 28.6× | 10.9× | 8.9% | 86.2% | 32.9% | 21.2% | 21.2% | — | 1,609 |
| BMY | $129.4B | 18.4× | — | 2.7× | -0.2% | 71.1% | 14.6% | 38.2% | 11.1% | — | 2,431 |
| MDT | $118.5B | 24.8× | 12.6× | 3.3× | 8.4% | 65.0% | 13.2% | 9.7% | 9.4% | 0.2× | 2,114 |
| LGVN | $117.4B | — | — | 97924.4× | -49.9% | 67.0% | -1894% | -400% | -400% | — | 31 |
| CVS | $116.6B | 66.0× | 11.7× | 0.3× | 7.8% | 45.0% | 0.4% | 2.4% | 2.4% | 0.0× | 1,795 |
| SYK | $108.8B | 33.9× | 18.7× | 4.3× | 11.2% | 64.0% | 12.9% | 14.5% | 8.5% | 2.5× | 2,196 |
| MCK | $103.4B | 23.1× | 16.3× | 0.3× | 12.4% | 3.6% | 1.2% | -219% | 109% | 1.0× | 1,946 |
| HCA | $96.7B | 15.2× | — | 1.3× | 7.1% | — | 9.0% | -113% | 16.8% | — | 1,346 |
| ELV | $91.1B | 16.4× | 15.4× | 0.5× | 12.5% | 89.4% | 2.8% | 12.9% | 7.6% | 4.2× | 1,397 |
| REGN | $81.0B | 18.7× | 19.4× | 5.7× | 1.0% | — | 31.4% | 14.4% | 13.6% | 0.5× | 1,336 |
| CRL | $13.5B | — | 30.9× | 3.4× | -0.9% | — | -3.6% | -4.6% | -4.6% | 0.0× | 532 |
Peers = companies sharing CRL's sector (Healthcare) with collected SEC financials. Multiples use the most recent end-of-day close and latest fiscal-year fundamentals (trailing, not forward). Missing cells mean the peer never reported that line item, has no collected price, or has a non-positive denominator. Not investment advice.